Work

Poster: AML-143 Trial in Progress: Phase Ib/II Study of Siremadlin in Combination With Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy (IC)

Year: 2022

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(22)00830-8

Authors: Naval G. Daver, Andrew H. Wei, Eytan M. Stein, Daniel J. DeAngelo, Dhrubajyoti Pathak, Yunnan Xu, Stephanie Grzesiak, Adriano Venditti

Institutions: The University of Texas MD Anderson Cancer Center, The Royal Melbourne Hospital, Peter MacCallum Cancer Centre, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Novartis (Switzerland), University of Rome Tor Vergata

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4296533015

FWCI:

Cites:

Cited by:

Related to: 10